<html>

    <head>
  <meta charset="utf-8">
  <title>Integration of Magnetic Resonance Imaging and Protein and Metabolite CSF Measurements to Enable Early Diagnosis of Secondary Progressive Multiple Sclerosis | pharmb.io - Pharmaceutical Bioinformatics Research Group at Uppsala University</title>
  <meta content="width=device-width, initial-scale=1" name="viewport">
  <meta content="Webflow" name="generator">
  <link href="/css/normalize.css" rel="stylesheet" type="text/css">
  <link href="/css/webflow.css" rel="stylesheet" type="text/css">
  <link href="/css/pharmbio.webflow.css?1704802922" rel="stylesheet" type="text/css">
  <script src="https://ajax.googleapis.com/ajax/libs/webfont/1.4.7/webfont.js"></script>
  <script type="text/javascript">
    WebFont.load({
      google: {
        families: ["Ubuntu:300,300italic,400,400italic,500,500italic,700,700italic","Raleway:regular,500,600,700,800,900"]
      }
    });
  </script>
  <script src="/js/modernizr.js" type="text/javascript"></script>
  <link href="/img/pharmbio_logo_square_64x64.png" rel="shortcut icon" type="image/x-icon">
  <link href="/img/pharmbio_logo_square_64x64.png" rel="apple-touch-icon">
  <script>
    (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
    (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
    m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
    })(window,document,'script','https://www.google-analytics.com/analytics.js','ga');

    ga('create', 'UA-86146183-1', 'auto');
    ga('send', 'pageview');
  </script>
</head>


    
  <div class="section-header" id="section-header">
    <div class="section-header-container w-container">
      <div class="navbar w-nav" data-animation="default" data-collapse="medium" data-contain="1" data-doc-height="1" data-duration="400" data-no-scroll="1">
        <div class="navbar-container w-container">
          <a class="navbar-brand w-nav-brand" href="/">
              <img class="navbar-logo" src="/img/pharmbio-logo-new.png">
          </a>
          <div class="navbar-menubutton w-nav-button">
            <div class="w-icon-nav-menu"></div>
          </div>
          <a class="navbar-uulogo-link" href="http://farmbio.uu.se/forskning/researchgroups/pb/Data-intensive/" target="_blank"><img class="navbar-uulogo-img" src="/img/uulogo_64x64.png"></a>
          <nav class="navbar-menu w-nav-menu" role="navigation" style="float: right">
              
              <a class="navbar-link w-nav-link" href="/project/">Projects</a>
              
              <a class="navbar-link w-nav-link" href="/people/">People</a>
              
              <a class="navbar-link w-nav-link" href="/infrastructure/">Infrastructure</a>
              
              <a class="navbar-link w-nav-link" href="/publication/">Publications</a>
              
              
              
              <a class="navbar-link w-nav-link" href="/tool/">Tools</a>
              
              <a class="navbar-link w-nav-link" href="/education/">Education</a>
              
              <a class="navbar-link w-nav-link" href="/about/">About</a>
              
              
              
              
              
              
              
          </nav>
        </div>
      </div>
    </div>
  </div>

              <div>
          <div class="section-content-container w-container content">

        <h1 style="font-size: 1.4em">Integration of Magnetic Resonance Imaging and Protein and Metabolite CSF Measurements to Enable Early Diagnosis of Secondary Progressive Multiple Sclerosis</h1>
        <p><a href="/publication">&larr; Back to publications</a></p>

        <p>Published: 2018-06-27</p>

        <h4>Formatted citation</h4>
        <p>
            Herman S, Khoonsari PE, Tolf A, Steinmetz J, Zetterberg H, Åkerfeldt T, Jakobsson P-J, Larsson A, Spjuth O, Burman J, Kultima K.
            <a href="http://dx.doi.org/10.7150/thno.26249" target="_blank">Integration of Magnetic Resonance Imaging and Protein and Metabolite CSF Measurements to Enable Early Diagnosis of Secondary Progressive Multiple Sclerosis</a>.
            <br><em>Theranostics</em>.
            <strong>8</strong>, 16, 4477-4490. (2018).
            DOI: <a href="http://dx.doi.org/10.7150/thno.26249" target="_blank">10.7150/thno.26249</a>
            
        </p>
        <h4>Abstract</h4>
        <p>Molecular networks in neurological diseases are complex. Despite this fact, contemporary biomarkers are in most cases interpreted in isolation, leading to a significant loss of information and power. We present an analytical approach to scrutinize and combine information from biomarkers originating from multiple sources with the aim of discovering a condensed set of biomarkers that in combination could distinguish the progressive degenerative phenotype of multiple sclerosis (SPMS) from the relapsing-remitting phenotype (RRMS). Methods: Clinical and magnetic resonance imaging (MRI) data were integrated with data from protein and metabolite measurements of cerebrospinal fluid, and a method was developed to sift through all the variables to establish a small set of highly informative measurements. This prospective study included 16 SPMS patients, 30 RRMS patients and 10 controls. Protein concentrations were quantitated with multiplexed fluorescent bead-based immunoassays and ELISA. The metabolome was recorded using liquid chromatography-mass spectrometry. Clinical follow-up data of the SPMS patients were used to assess disease progression and development of disability. Results: Eleven variables were in combination able to distinguish SPMS from RRMS patients with high confidence superior to any single measurement. The identified variables consisted of three MRI variables: the size of the spinal cord and the third ventricle and the total number of T1 hypointense lesions; six proteins: galectin-9, monocyte chemoattractant protein-1 (MCP-1), transforming growth factor alpha (TGF-α), tumor necrosis factor alpha (TNF-α), soluble CD40L (sCD40L) and platelet-derived growth factor AA (PDGF-AA); and two metabolites: 20β-dihydrocortisol (20β-DHF) and indolepyruvate. The proteins myelin basic protein (MBP) and macrophage-derived chemokine (MDC), as well as the metabolites 20β-DHF and 5,6-dihydroxyprostaglandin F1a (5,6-DH-PGF1), were identified as potential biomarkers of disability progression. Conclusion: Our study demonstrates, in a limited but well-defined and data-rich cohort, the importance and value of combining multiple biomarkers to aid diagnostics and track disease progression.</p>

            </div>
</div>

      <div class="section-footer">
    <div class="section-footer-container w-container">
        
        <div class="footer-text">
            <p>
            <strong>Pharmaceutical Bioinformatics Research Group</strong><br>
            Department of Pharmaceutical Biosciences<br>
            Uppsala University, Sweden<br>
            GitHub: <a href="https://github.com/pharmbio">github.com/pharmbio</a>
            </p>
        </div>
    </div>
  </div>

  <script src="https://ajax.googleapis.com/ajax/libs/jquery/2.2.0/jquery.min.js" type="text/javascript"></script>
  <script src="/js/webflow.js" type="text/javascript"></script>
  
</body>
</html>

